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Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and β-cell dysfunction. Among available oral antidiabetic 
agents, only the thiazolidinediones (TZDs) primarily target insulin resistance. TZDs improve insulin sensitivity by activating per-
oxisome proliferator-activated receptor γ. Rosiglitazone and pioglitazone have been used widely for T2DM treatment due to their 
potent glycemic efficacy and low risk of hypoglycemia. However, their use has decreased because of side effects and safety issues, 
such as cardiovascular concerns and bladder cancer. Lobeglitazone (Chong Kun Dang Pharmaceutical Corporation), a novel 
TZD, was developed to meet the demands for an effective and safe TZD. Lobeglitazone shows similar glycemic efficacy to piogli-
tazone, with a lower effective dose, and favorable safety results. It also showed pleiotropic effects in preclinical and clinical studies. 
In this article, we summarize the pharmacologic, pharmacokinetic, and clinical characteristics of lobeglitazone.
Keywords: Diabetes mellitus, type 2; Lobeglitazone; Thiazolidinediones
Corresponding author: Bong-Soo Cha  https://orcid.org/0000-0003-0542-2854
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei 
University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea 
E-mail: BSCHA@yuhs.ac
*Jaehyun Bae and Taegyun Park contributed equally to this study as first authors.
Received: Nov. 16, 2020; Accepted: Feb. 23, 2021
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic progressive met-
abolic disease characterized by insulin resistance and β-cell 
dysfunction [1]. Because the pathophysiology of T2DM is 
complex and multifactorial, a variety of oral antidiabetic agents 
(OADs) have been developed based on the underlying mecha-
nisms associated with T2DM. Among the OADs developed so 
far, the thiazolidinedione (TZD) class is one of the classes of 
OADs which primarily targets insulin resistance [2].
TZDs improve insulin sensitivity by activating peroxisome 
proliferator-activated receptor γ (PPARγ) [3] and were intro-
duced as an OAD class in the late 1990s. The first TZD ap-
proved for T2DM treatment was troglitazone, which was with-
drawn from the market in 2000 because of hepatotoxicity [4]. 
Other TZDs, rosiglitazone and pioglitazone, were approved by 
the U.S. Food and Drug Administration in 1999 and have been 
used widely for T2DM treatment due to their potent glycemic 
efficacy and low risk of hypoglycemia. They have also shown 
excellent glycemic durability [5,6]. However, because of side 
effects and safety issues, such as cardiovascular concerns [7] 
and bladder cancer [8], the use of rosiglitazone and piogli-
tazone has been restricted or decreased significantly during the 
2010s.
Lobeglitazone (Chong Kun Dang Pharmaceutical Corpora-
tion, Seoul, Korea) is a novel TZD, developed to meet the de-
mands for an effective and safe TZD. Its development program 
was initiated in May 2000 by Chong Kun Dang Pharmaceuti-
cal Corporation and it was approved for the management of 
T2DM in Korea in July 2013.
Although there is still a need for further studies, lobegli-
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in studies performed to date. In this article, we will review the 




Lobeglitazone is a pharmacophore which has a 2,4-thiazolidin-
edione group with an ethoxy-benzyl N-methylamino group 
bound to this as a connecting link. Its structural formula is 
C24H24N4O5S, and the chemical name is 5-[4-(2-{[6-(4-Me-
thoxy-phenoxy)-pyrimidin-4-yl]-methyl-amino}-ethoxy)-
benzyl]-thiazolidine-2,4-dione hydrosulphuric acid. The co-
crystal structure of lobeglitazone with PPARγ is shown in Sup-
plementary Fig. 1.
Lobeglitazone was based on modification of the rosigli-
tazone structure to introduce a p-methoxyphenoxy group at 
the 4-position of the pyrimidine moiety [9]. This contributes 
to enhanced binding affinity of lobeglitazone for PPARγ, with 
docking analysis suggesting that the binding affinity of lobegli-
tazone is 12 times higher than that of rosiglitazone and piogli-
tazone [9]. The p-methoxyphenoxy group enables extended 
interaction with the hydrophobic pocket, and this could also 
affect the cyclin dependent kinase 5-mediated phosphoryla-
tion of PPARγ at Ser245, which changes the expression of 
genes such as adiponectin and adipsin that are associated with 
insulin sensitivity without general transcriptional activity of 
PPARγ [10].
Metabolic effects: preclinical studies
The effect of lobeglitazone on PPARγ activity was assessed by 
time-resolved fluorescence resonance energy transfer (TR-
FRET) assay. The half maximal effective concentration (EC50) 
of lobeglitazone for PPARγ was 0.1374 μM, and it showed se-
lectivity for PPARγ (PPARα/PPARγ EC50 ratio=3,976) [11]. 
The EC50 values of rosiglitazone and pioglitazone for PPARγ 
were 0.1076 and 0.5492 μM, respectively.
In in vivo studies, lobeglitazone showed a significant glu-
cose-lowering effect in Zucker diabetic fatty (ZDF) rats, db/db 
and KK/Upi-Ay/J (KKAy) mice. Lobeglitazone acted in a dose-
dependent manner and was most effective at 0.3 mg/kg, at 
which dose it was equivalent to 30 mg/kg of pioglitazone [11]. 
Lobeglitazone increased glucose uptake in 3T3-L1 adipocytes 
and L6 muscle cells, with the effects greater than those ob-
served with pioglitazone [11], and showed beneficial effects on 
pancreatic β-cell survival in db/db mice [12,13]. It was also 
found to inhibit protein tyrosine phosphatase 1B in vitro; this 
enzyme is involved in the regulation of insulin and leptin sig-
naling and is implicated in the development of insulin resis-
tance and T2DM [14].
Other metabolic effects of lobeglitazone have also been eval-
uated. The effect of lobeglitazone on lipid profiles was com-
pared to that of pioglitazone in ZDF rats, with plasma triglyc-
eride (TG) and free fatty acid (FFA) levels reduced similarly in 
both treatment groups (TG reduced by 77% with lobeglitazone 
10 mg/kg and 75% with pioglitazone 10 or 30 mg/kg; FFA re-
duced by 98% with lobeglitazone 10 mg/kg and 97% with pio-
glitazone 10 or 30 mg/kg) [11]. Lobeglitazone enhanced lipid 
accumulation and, adipocyte differentiation through increas-
ing the expression of genes regulated by PPARγ such as adipo-
cyte proterin 2 (aP2), and CD36 to a greater extent than seen 
with other TZDs in vitro [11]. Long-term administration of 
lobeglitazone had a beneficial role on adipose tissue remodel-
ing, by inducing differentiation of preadipocytes into insulin-
sensitive small adipocytes, and redistribution from visceral to 
subcutaneous adipose depots, and induced the differentiation 
of white adipocytes to beige adipocytes and was associated 
with the development of brown adipocytes [13]. Lobeglitazone 
also enhanced beige adipocyte formation and thermogenic 
gene expression in lean mice after cold exposure, to a greater 
extent than observed with pioglitazone or rosiglitazone [15].
Potential pleiotropic effects: preclinical studies
Similar to the therapeutic effect of pioglitazone on fatty liver, 
lobeglitazone also attenuated hepatic steatosis in obese mice by 
increasing insulin sensitivity and inhibiting hepatic lipogenesis 
[16,17].
A few studies have reported favorable effects of lobeglitazone 
on atherosclerosis in in vitro or in vivo models [18,19]. Lobegl-
itazone significantly reduced neointimal formation after bal-
loon injury in rat carotid arteries and reduced the atheroma-
tous burden in the aorta of ApoE−/− mice fed with a high-fat/
high-cholesterol diet [18]. These results were in line with pre-
vious studies showing that PPARγ activation inhibits vascular 
smooth muscle cell proliferation and inflammatory pathways 
and, therefore, TZDs might be expected to protect or relieve 
the endothelium from atherosclerosis [20,21]. Lobeglitazone 
also inhibited the formation of lipid droplets in foam cells in 
an in vitro model [22].
Anti-inflammatory characteristics of lobeglitazone were evi-
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dent in a murine model of asthma [23], and lobeglitazone im-
proved renal fibrosis in mice by inhibiting transforming 
growth factor-β/Smad signaling [24].
These preclinical studies suggest that lobeglitazone might 
have beneficial effects on various organs; however, clinical 
studies are needed to evaluate the potential role of lobegli-
tazone in these settings.
Other studies evaluated potential safety concerns with 
TZDs, including bone health and cancer risk. Both adipocytes 
and osteoblasts differentiate from mesenchymal stem cells, a 
process that is in part regulated by PPARγ [25]. Consequently, 
there is a concern that long-term administration of TZDs 
could have adverse effects on bone, as was seen with rosigli-
tazone which reduced bone mineral density (BMD) [26,27]. 
Studies with lobeglitazone found that it did not inhibit osteo-
blast differentiation in vitro and had no adverse effect on BMD 
in mice [25].
Finally, there is evidence that some PPAR agonists, such as 
pioglitazone, may increase the risk of bladder cancer [28,29]. 
Long-term studies in rats and mice suggested that lobegli-
tazone had a low carcinogenic potential and did not induce 
urothelial tumors [30,31].
Pharmacokinetics
Data on the pharmacokinetics of lobeglitazone have been ob-
tained from healthy volunteers and patients with renal impair-
ment.
Healthy adults
After single oral doses of lobeglitazone in healthy male subjects, 
peak plasma levels of lobeglitazone were reached at 1 to 3 hours 
and then declined monoexponentially with a half-life of 7.8 to 
9.8 hours [32]. In males, peak plasma concentration (Cmax) and 
area under the plasma concentration–time curve from time 0 
to infinity (AUCinf) increased in a dose-proportional manner 
across the dose range of 1 to 4 mg [32]. After multiple-dose ad-
ministration (once-daily regimen) in healthy males, lobegli-
tazone reached steady-state concentrations by day 5, and no 
clinically significant drug accumulation was observed [32].
When a single doses of lobeglitazone was administered to 
healthy female subjects, systemic lobeglitazone exposure after 
2 mg was similar to that seen in males, but after administration 
of 4 mg, exposure was 2.36-fold greater in females than in 
males [33]. However, dose adjustment based on sex alone is not 
necessary because the approved dose for clinical use is lower 
(0.5 mg/day). Pharmacokinetic parameters after a single dose 
of lobeglitazone 0.5 mg in males are summarized in Table 1.
Lobeglitazone clearance was mainly mediated by liver me-
tabolism and the ratio of renal excretion was predicted to be 
<1.0% [32]. Based on an in vitro human liver microsomal 
study, the main cytochrome P450 (CYP) isoforms involved in 
the hepatic metabolism of lobeglitazone were cytochrome 
P450 3A4 (CYP3A4), 2C19, and 2D6 [11].
Food interaction
In a study that evaluated the effect of food on the pharmacoki-
netics of a single dose of lobeglitazone 1 mg, a slight increase in 
the AUC for lobeglitazone was observed in subjects who were 
receiving a high lipid diet compared with fasting subjects [11]. 
There were no significant between-group differences in the 
Cmax of lobeglitazone or its active metabolite M7, and the slight 
increase in bioavailability with a high lipid diet was not consid-
ered to be clinically significant.
In a study evaluating a fixed-dose combination tablet con-
taining lobeglitazone 0.5 mg plus metformin extended-release 
1,000 mg, lobeglitazone Cmax decreased by approximately 32% 
when administered after a high-fat meal compared with the 
Table 1. Summary of lobeglitazone pharmacokinetic parame-









Protein binding, % 99.3–99.9
Metabolism CYP 3A4 (main), 2C19 and 2D6
Metabolites M7 (O-demethylation; main), 
M9 (N-demethylation)
Values are presented as mean±standard deviation unless indicated 
otherwise.
Tmax, time to Cmax; Cmax, maximum plasma concentration; AUCinf, area 
under concentration–time curve from 0 to infinity; CL/F, oral clear-
ance; t1/2, elimination half-life; fe, fraction excreted unchanged in 
urine; CYP, cytochrome P450. 
aMedian and range are presented for Tmax, bFraction of lobeglitazone 
excreted unchanged in urine was below the lower limit of quantifica-
tion (0.2 ng/mL).
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fasting state; however, there was no significant difference be-
tween the fed and fasted states with respect to lobeglitazone 
AUC up to the last sampling time [34].
Patients with renal impairment
An open-label, parallel-group, single-dose, non-randomized 
study was conducted to evaluate the pharmacokinetic profile 
of lobeglitazone in patients with renal impairment [11]. The 
geometric means for Cmax and AUC in patients with end-stage 
renal disease (ESRD) were similar to those for subjects with 
normal renal function (Table 2). Cmax and AUCinf values for M7 
(the active metabolite of lobeglitazone) were 1.22 and 1.31 
times higher in the ESRD group compared with the control 
group. However, overall, the pharmacokinetic profiles did not 
differ significantly between the two groups (Table 2).
Drug interactions
In studies evaluating potential drug–drug interactions in 
healthy male volunteers, no significant changes were observed 
in the pharmacokinetics of either drug when lobeglitazone was 
coadministered with other antidiabetic agents including met-
formin, glimepiride, dapagliflozin, and sitagliptin [11,35-37]. 
In general, the 90% confidence intervals (CIs) for the geomet-
ric mean ratios (combination vs. single drug) for Cmax and 
AUC were within the conventional equivalence range of 80% 
to 120%. Exceptions were a slightly increased steady-state Cmax 
for sitagliptin (ratio, 1.1694; 90% CI, 1.0740 to 1.27320) and a 
slightly decreased Cmax for glimepiride (ratio, 0.910547; 90% 
CI, 0.78246 to 1.05960), when each was coadministered with 
lobeglitazone; however, neither of these changes were consid-
ered to be clinically significant [11,37].
There were also no significant changes in the pharmacoki-
netics of either drug when lobeglitazone was coadministered 
with amlodipine or warfarin [38,39]. However, coadministra-
tion with ketoconazole, a strong CYP3A4 inhibitor, increased 
the level of exposure to lobeglitazone by about 33% (geometric 
mean ratio for AUCinf, 1.33; 90% CI, 1.23 to 1.44) [40].
LOBEGLITAZONE CLINICAL PROFILE
Glycemic control in type 2 diabetes mellitus
Monotherapy
The short-term glycemic efficacy of lobeglitazone was initially 
evaluated in a randomized, double-blind, placebo-controlled, 
phase II study. Patients with T2DM (n=241) received lobegli-
tazone 0.5 mg (n=55), 1 mg (n=54), or 2 mg (n=50), or place-
bo (n=55) for 8 weeks [11]. Changes in fasting plasma glucose 
levels after 8 weeks of treatment (primary endpoint) were 
–20.65 mg/dL (0.5 mg), –23.38 mg/dL (1 mg), –33.69 mg/dL 
(2 mg), and –1.8 mg/dL (placebo). The frequency of edema in-
creased with the higher doses of lobeglitazone, and therefore 
the minimum effective dose of 0.5 mg once daily was selected 
as the standard dose for further evaluation.
Subsequently, a phase III study compared the glycemic effi-
cacy of lobeglitazone 0.5 mg (n=115) with placebo (n=58) 
over 24 weeks [41]. Mean changes in glycosylated hemoglobin 
(HbA1c) from baseline to week 24 (primary endpoint) were 
–0.44% in the lobeglitazone group versus 0.16% in the placebo 
group (mean difference, –0.6%; P<0.0001). In a 28-week open-
label extension study, patients who completed the 24-week 
study either continued on lobeglitazone (n=65) or switched 
from placebo to lobeglitazone (n=29) [42]. In those patients 
who received lobeglitazone for 52 weeks, the decrease in 
HbA1c seen at week 24 was maintained during the extension 
period; the mean change in HbA1c from baseline to week 52 
was –0.50%. In patients who switched from placebo to lobegli-
tazone at week 25, HbA1c improved after administration of 
lobeglitazone and the mean change in HbA1c from baseline to 
week 52 was –0.52%, similar to that seen in the group who re-
mained on lobeglitazone for the entire 52 weeks.
Table 2. Pharmacokinetic profiles in subjects with end-stage renal disease [11]
Parameter ESRD Normal Geometric mean ratio 90% CI
Cmax, ng/mL 45.56±10.815 46.43±7.157 0.9883 0.8441–1.1572
AUC48, ng/hr/mL 669.29±266.348 750.19±206.071 0.8683 0.6319–1.1931
AUCinf, ng/hr/mL 803.27±366.626 964.57±313.819 0.8039 0.5507–1.1737
Values are presented as mean±standard deviation.
ESRD, end-stage renal disease; CI, confidence interval; Cmax, maximum plasma concentration; AUC48, area under concentration–time curve 
from 0 to 48 hours; AUCinf, area under concentration–time curve from 0 to infinity.
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Combination therapy
The antihyperglycemic effect of lobeglitazone in combination 
with metformin was evaluated in a 24-week, randomized, 
double-blind, non-inferiority trial [43]. Patients with T2DM 
whose blood glucose levels were inadequately controlled 
(HbA1c 7% to 10%) despite a stable dose of metformin 
(≥1,000 mg/day) were randomized to receive lobeglitazone 0.5 
mg daily (n=128) or pioglitazone 15 mg daily (n=125) as add-
on therapy to metformin. After 24 weeks of lobeglitazone add-
on therapy, the mean change in HbA1c (primary endpoint) 
was −0.74%, which was almost the same as the change seen in 
the pioglitazone group (mean difference, 0.01%; 95% CI, 
–0.16% to 0.18%), indicating that lobeglitazone was not inferi-
or to pioglitazone as add-on therapy to metformin with respect 
to the glucose-lowering effect.
In another randomized controlled study, 24 weeks of treat-
ment with lobeglitazone (n=121) as an add-on to metformin 
was non-inferior to sitagliptin add-on therapy (n=126) with 
respect to glycemic efficacy (mean change in HbA1c –0.79% 
vs. –0.86%; difference, 0.08%; 95% CI, –0.14% to 0.30%) [44].
Apart from metformin, no prospective randomized studies 
comparing the glycemic efficacy of dual-combination therapy 
containing lobeglitazone versus other OADs have been pub-
lished to date. However, a retrospective study assessed the gly-
cemic efficacy of lobeglitazone as monotherapy and in various 
forms of combination therapy [45]. The study, conducted in a 
routine clinical practice setting, analyzed 423 patients who 
took lobeglitazone for more than 180 consecutive days (aver-
age age 62.7 years, average duration of T2DM 8.5 years, base-
line HbA1c 7.5%). After a median of 350 days of lobeglitazone 
treatment, the mean change in HbA1c was –0.6% overall; for 
lobeglitazone monotherapy it was –0.34%, for combination 
therapy with metformin it was –0.52%, in combination with 
dipeptidyl peptidase-4 (DPP-4) inhibitors –0.63%, and in 
combination with a sulfonylurea –0.33%. Regarding the triple 
therapy, the mean change in HbA1c was –0.84% for patients 
taking lobeglitazone, metformin, and DPP-4 inhibitor, –0.88% 
for those taking lobeglitazone, DPP-4 inhibitor and sulfonyl-
urea, and –0.33% for those taking lobeglitazone, metformin, 
and sulfonylurea. These results suggested that when lobegli-
tazone is treated in combination with DPP-4 inhibitor, it would 
improve blood glucose levels more potently than other lobegli-
tazone-combining regimens.
Recently, a prospective observational study specifically eval-
uated the effect of initial triple combination therapy including 
lobeglitazone for drug-naïve patients with T2DM with an 
HbA1c level from 9.0% to 12.0% [46]. This study enrolled pa-
tients consecutively and used matching based on age and body 
mass index to select a comparator group who were treated with 
conventional stepwise dual therapy. After 12 months, HbA1c 
had decreased by a mean of 4.05% among recipients of initial 
triple therapy comprising metformin 1,000 mg/day plus sita-
gliptin 100 mg/day plus lobeglitazone 0.5 mg/day compared 
with 3.28% among recipients of uptitrated treatment with met-
formin ≥1,000 mg/day plus glimepiride ≥2 mg/day (P<0.05). 
Although this study focused on the effectiveness of the initial 
triple therapy, it also provided evidence for the efficacy and 
safety of lobeglitazone as a combination therapy for T2DM.
Indirect comparison with pioglitazone
No randomized studies have directly compared lobeglitazone 
with pioglitazone as monotherapy. An indirect comparison of 
the glycemic efficacy of lobeglitazone with pioglitazone based 
on relevant studies is summarized in Table 3, Fig. 1 [41-43,47-
51]. Among patients who had a similar level of glycemic con-
trol at baseline, lobeglitazone appeared to show similar glu-
Table 3. Glycemic efficacy of lobeglitazone in patients with 
type 2 diabetes mellitus: indirect comparison with pioglitazone 
based on prospective randomized controlled studies




   Week 24 16 26
   Baseline HbA1c, % 7.85 7.50 10.2









   Week 52 52 52
   Baseline HbA1c, % 7.79 8.69 8.70
   Change in HbA1c, % −0.50 −1.41a −1.40a
Add-on to metformin [43,51]
   Week 24 24 24
   Baseline HbA1c, % 7.93 7.96 8.40
   Change in HbA1c, % −0.74 −0.74b −0.98
HbA1c, glycosylated hemoglobin.
aStudy design allowed pioglitazone dose-titration to 45 mg/day, bStudy 
used pioglitazone 15 mg/day. All pioglitazone data not marked with 
superscript a or b are from studies which used pioglitazone 30 mg once 
a day.
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cose-lowering efficacy to pioglitazone. Although the results of 
some studies seemed to suggest that pioglitazone might have a 
more potent effect, it should be noted that those studies re-
cruited patients with higher baseline HbA1c.
Potential pleiotropic effects
Lipid profiles
Treatment with lobeglitazone for 24 weeks improved blood 
levels of TG, high-density lipoprotein cholesterol, and small 
dense low-density lipoprotein cholesterol (small dense LDL-
C) [41]. Improvements in TG and small dense LDL-C re-
mained statistically significant during a 28 week-extension pe-
riod [42]. Similar effects on lipid profiles were seen in the study 
of lobeglitazone as add-on therapy to metformin [43]. In that 
study, there were no significant differences in lipid parameters 
between lobeglitazone and pioglitazone. The effect of lobegli-
tazone on lipid profiless is summarized in Table 4.
Non-alcoholic fatty liver disease 
TZDs are one of the few oral agents recommended as a treat-
ment for non-alcoholic fatty liver disease (NAFLD) [52]. The 
effects of lobeglitazone on NAFLD were investigated in a sin-
gle-arm study using transient liver elastography (Fibroscan; 
Echosens, Paris, France), as well as glycemic, lipid, and liver 
enzyme profiles [53]. Fifty T2DM patients with NAFLD, de-
fined as controlled attenuation parameter (CAP) ≥250 dB/m, 
received lobeglitazone 0.5 mg once daily. After 24 weeks, mean 
CAP significantly decreased (from 313.4±30.9 to 297.8±39.1 
dB/m, P=0.016). Liver enzymes including aspartate transami-
nase, alanine transaminase, and gamma glutamyl transferase 
also decreased. When patients were grouped as lobeglitazone 
responders and non-responders in terms of CAP changes, 
mean changes in HbA1c levels did not differ significantly be-
tween the groups, indicating that the therapeutic effect in 
NAFLD by lobeglitazone was independent of its glycemic effi-
cacy.
Fig. 1. Indirect comparison of glycemic efficacy between lobe-
glitazone and pioglitazone in patients with type 2 diabetes mel-
litus based on previous prospective randomized, controlled 
studies. (A) Monotherapy, short-term, (B) monotherapy, long-
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Safety and tolerability
Lobeglitazone was generally well tolerated as monotherapy 
and in combination with metformin (with or without sita-
gliptin) [41-43,46]. The proportions of adverse events were 
similar between the lobeglitazone and placebo groups in the 
placebo-controlled monotherapy trial [41,42] and the lobegli-
tazone and pioglitazone groups (Table 5) [43] as well as be-
tween the lobeglitazone and sitagliptin groups [44] in the ac-
tive-controlled metformin combination therapy trials. 
Peripheral edema, one of the most frequent side effects asso-
ciated with TZDs, occurred in 3.6% of patients treated with 
lobeglitazone monotherapy for 24 weeks [41], and 3.1% of pa-
tients by the end of the monotherapy extension study (total 52 
weeks) [42]. No patients had severe edema requiring treatment 
discontinuation. When lobeglitazone was administered in 
combination with metformin, 3.9% of patients experienced 
edema within 24 weeks, with no cases of severe edema [43]. In 
another study, peripheral edema and facial edema occurred in 
1.67% and 3.33% of patients treated with lobeglitazone as add-
on therapy to metformin [44]. The incidence of peripheral 
edema seems to be acceptable, considering that the frequency 
of peripheral edema in clinical studies using pioglitazone 
monotherapy ranged from 3.6% to 28.9% [47-49,54-56]. 
Weight gain is expected in patients treated with TZDs [2,57]. 
In the monotherapy trial, the mean bodyweight gain in the 
lobeglitazone group after 24 weeks was 0.89 kg, whereas in the 
placebo group bodyweight changed by –0.63 kg (mean differ-
ence, 1.52 kg; P<0.0001) [41]. When used as add-on therapy 
to metformin, mean weight gain was 0.92 kg in the lobegli-
tazone group, which did not differ significantly from that of 
the pioglitazone group (0.76 kg, P=0.569) [43]. Weight gain 
was greater with lobeglitazone than with sitagliptin when used 
as add-on therapy to metformin (mean difference, 1.34 kg; 
P<0.0001) [44].
Hypoglycemia was not reported in the monotherapy trial 
[41,42], while one subject (0.8%) in the lobeglitazone group 
versus three subjects (2.4%) in the pioglitazone group reported 
hypoglycemia when they were used as add-on therapy to met-
formin [43].
A potential concern with TZDs is an increased risk of bone 
fractures associated with reduced BMD [2]. The monotherapy 
trial [41,42] incorporated an evaluation of femur neck and to-
tal hip BMD using dual-energy X-ray absorptiometry at week 
24 and the week 52, and found no statistically significant dif-
ference in change in BMD between lobeglitazone and placebo 
[58]. Longer-term and mechanistic studies are needed to con-
firm this finding.
Other potential concerns with some TZDs include heart 
Table 4. Effects on lipid parameters of lobeglitazone as monotherapy or combination therapy
Variable Total cholesterol, mg/dL
LDL-C,
mg/dL






Free fatty acid, 
µEq/L
Monotherapy [41]
   Lobeglitazone
      Baseline 178.70 109.0 8.10 48.69 137.51 622.28
      Change 6.0 0.95 −1.7a,b 4.3a,b −19.06a,b −60.39a,b
   Placebo
      Baseline 188.26 114.76 9.51 46.33 177.14 699.57
      Change 4.84 −2.64 0.62 0.76 16.14 −1.0
Add-on to metformin [43]
   Lobeglitazone
      Baseline 162.03 88.55 4.02 49.50 139.95 680.0
      Change 6.96a 4.64a −1.23a 4.64a −12.40a −100.0a
   Pioglitazone
      Baseline 169.76 95.13 5.07 49.11 156.78 660.0
      Change 7.35a 4.64a −1.06a 5.80a −19.49a −90.0a
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
aP<0.05 vs. baseline, bP<0.05 vs. placebo.
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failure and bladder cancer [2]. Neither of these were observed 
in either the lobeglitazone monotherapy or combination ther-
apy trials. Due to the small sample sizes and short study dura-
tions, these studies cannot definitively confirm the long-term 
clinical benefits and risks, and further research is needed to as-
sess cardiovascular outcomes and the risk of bladder cancer 
with lobeglitazone. However, the risk of bladder cancer with 
lobeglitazone is considered low based on preclinical studies 
[30,31] and its negligible urinary excretion [9,32].
Ongoing studies
Several clinical studies instigated by CKD Pharmaceutical 
Corp are currently ongoing, and the results are not yet avail-
able. These include efficacy and safety trials of lobeglitazone as 
add-on combination therapy with DPP-4 inhibitors (Clinical-
Trial.gov registration number: NCT03641352), sodium glu-
cose cotransporter-2 (SGLT-2) inhibitors (ClinicalTrial.gov 
registration number: NCT03627182) and insulin (cris.nih.
go.kr registration number: KCT0002852), a comparison of 
changes in HbA1c between lobeglitazone 0.25 and 0.5 mg in 
patients with T2DM (ClinicalTrial.gov registration number: 
NCT03770052), and additional pharmacokinetic and drug–
drug interaction studies with DPP-4 inhibitors (ClinicalTrial.
gov registration number: NCT04431687) and SGLT-2 inhibi-
tors (ClinicalTrial.gov registration number: NCT04334213).
CONCLUSIONS
Based on the studies summarized in this review, lobeglitazone 
is a novel TZD with potent efficacy and a favorable safety pro-
file. Lobeglitazone shows similar glycemic efficacy to piogli-
tazone, with a lower effective dose, owing to its higher affinity 
to PPARγ. Because lobeglitazone is mainly metabolized by the 
liver, with negligible renal excretion, it is expected that it can 
be used in patients with renal insufficiency without dose re-
duction, and it may have a lower risk of bladder cancer than 
other TZDs. Clinical trials conducted to date also have shown 
favorable results on safety of lobeglitazone. Additional clinical 




















Any AE 55 (49.1) 30 (51.7) 41 (64.1) 18 (62.1) 66 (51.6) 64 (51.2)
Drug-related AE 10 (8.9) 3 (5.2) 8 (12.5) 2 (6.9) 8 (6.3) 6 (4.8)
Serious AE 4 (3.6) 0 3 (4.7) 0 7 (5.5) 6 (4.8)
Frequent AE 
Hyperglycemia 3 (2.7) 4 (6.9) 3 (4.7) 0 <3%b <3%b
Nasopharyngitis 6 (5.4) 0 3 (4.7) 0 6 (4.7) 10 (8.0)
URTI 2 (1.7) 3 (5.2) 8 (12.5) 1 (3.5) 2 (1.6) 4 (3.2)
Peripheral edema 4 (3.6) 0 2 (3.1) 0 (0) 5 (3.9) 2 (1.6)
Headache 3 (2.7) 2 (3.5) 3 (4.7) 1 (3.5) <3%b <3%b
Hematuria 3 (2.7) 3 (5.2) 3 (4.7) 2 (6.9) 0 0 
AE of special interest
Hypoglycemia 0 0 0 0 1 (0.8) 3 (2.4)
Heart failure 0 0 0 0 <3%b <3%b
Ischemic heart disease 0 0 0 0 <3%b <3%b
Neoplasm 1c (0.9) 0 1c (1.6) 0 0 1d (0.8)
Values are presented as number (%).
AE, adverse event; URTI, upper respiratory tract infection.
aMaintenance group received lobeglitazone for weeks 0–52. Switch group received placebo for weeks 0–24 and lobeglitazone for weeks 25–52, 
bExact number of cases not presented in the published article, cLung cancer, not considered to be related to lobeglitazone by investigators, 
dColon cancer, not considered to be related to pioglitazone by investigators.
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and preclinical studies are expected to provide further evi-
dence of the beneficial effects of lobeglitazone and its mecha-
nism of action.
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